Windward Bio (WWB.US) plans to list in the US and aims to raise up to 100 million dollars, with multiple drugs licensed to Chinese pharmaceutical companies.

Zhitong Finance APP has learned that Switzerland-based clinical-stage biotechnology company Windward Bio Group filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) last Friday, aiming to raise up to 100 million USD.

Windward Bio is developing ultra-long-acting antibody drugs for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis, aiming to reduce dosing frequency. Its main candidate drug, WIN378, targets TSLP and shares the same target as the already approved drug Tezspire, but differs in dosing frequency: WIN378 is designed to be administered once every six months, while Tezspire is administered once every four weeks. The company is currently conducting Phase II/III clinical trials of WIN378 for severe uncontrolled asthma and Phase II clinical trials for COPD. The primary results of the Phase II asthma trial are expected to be released in the first half of 2027.

The company's second candidate drug, WIN027, is a bispecific antibody targeting both TSLP and IL-13, and is in Phase I clinical trials. The company plans to initiate Phase II clinical trial enrollment for COPD and atopic dermatitis in the first half of 2027. Windward Bio has obtained a license for WIN378 from Kelun-Biotech and Harbour BioMed, and a license for WIN027 from QxBio.

Windward Bio was founded in 2024 and is headquartered in Basel, Switzerland. The company plans to list on Nasdaq under the stock code “WWB”. It confidentially filed for listing on July 24, 2026. Jefferies, TD Securities, Piper Sandler, and UBS Investment Bank are serving as joint bookrunners for the offering. Pricing terms for the issuance have not yet been disclosed.